SEATTLE, June 30, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the Global Next Generation Sequencing Market is estimated to be valued at US$ 12,870.5 million in 2022 and is expected to exhibit a CAGR of 18.3% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Next Generation Sequencing Market:
Major players operating in the market are focusing on adopting strategies such as product launches, which is expected to drive the market growth over the forecast period. For instance, in August 2020, Ancestry, a genealogy company, launched a new product which features next-generation sequencing. The new product aims to help customers gain insights into their health and risk factors. Called “AncestryHealth powered by Next Generation Sequencing,” the tool can screen for genes associated with breast cancer, heart disease, colon cancer and blood disorders.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/158
Key Market Takeaways:
The global next generation sequencing market is expected to exhibit a CAGR of 18.3% during the forecast period due to the increasing prevalence of infections. For instance, according to the World Health Organization Facts Sheet 2022, around 296 million people were living with chronic hepatitis B infection in 2019 globally
Among technology, the whole genome sequencing (WGS) segment is expected to dominate the segment growth over the forecast period, as numerous initiatives are being undertaken by universities and research institutions for utilizing WGS technology in identifying the cause of diseases. For instance, in February 2021, Stanford Medicine, an institute integrating a premier medical school with world-class hospitals to advance human health, launched in-house service for whole genome sequencing
On the basis of applications, the disease diagnosis segment is expected to dominate the segment growth over the forecast period, owing to the increasing approvals for next generation sequencing tests for the detection of diseases and the specimen causing the disease. For instance, in August 2020, Helix, the leading population genomics company, announced that it had received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Helix COVID-19 NGS Test. The test is an amplicon-based next-generation sequencing (NGS) test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens (nasopharyngeal swabs, oropharyngeal (throat) swab, mid-turbinate nasal swabs, and anterior nasal swabs) from individuals suspected of COVID-19 by their healthcare provider
Competitive Landscape:
Key players operating in the global next generation sequencing market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc, bioMérieux SA, F. Hoffmann-La Roche Ltd , QIAGEN, Illumina, Inc., Oxford Nanopore Technologies plc., BGI, PerkinElmer Genomics, and Pierian.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/158
Market Segmentation:
- Global Next Generation Sequencing Market, By Technology:
- Whole Genome Sequencing
- Whole Exome Sequencing
- RNA Sequencing
- Targeted Re-sequencing
- Others
- Global Next Generation Sequencing Market, By Application:
- Drug Discovery
- Personalized Medicine and Genetic Screening
- Disease Diagnosis
- Agriculture and Animal Research
- Others
- Global Next Generation Sequencing Market, By End User:
- Hospital
- Research Centers
- Pharma and Biotech Firms
- Others
- Global Next Generation Sequencing Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Region/Country
- North America
Related Market Intelligence Reports:
Immune Repertoire Sequencing Market, By Product Type (Assay Kits (T-Cell Receptor Kits, and B-Cell Receptor Kits) and Instruments), By Application (Cancer Immunotherapy, Biomarker Discovery, Autoimmune Diseases, Vaccine Development and Efficacy, Transplant Rejection and Tolerance, Infectious Diseases, and Other Applications), By End User (Diagnostic Labs, Biotechnology and Pharmaceutical Companies, Academic and Research Institutes, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
SNP Genotyping and Analysis Market, By Technology (SNP Microarray, Taqman Allelic Discrimination, SNP Pyrosequencing Technologies, ABISNPlex, Sequenom Mass-Array MALDI-TOF, Others), By Application (Pharmaceuticals and Pharmacogenomics, Diagnostic Research, Agricultural Biotechnology, Breeding and Animal Livestock), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
